Thread Rating:
  • 0 Vote(s) - 0 Average
  • 1
  • 2
  • 3
  • 4
  • 5
OT: Coronavirus
Quote: @BigAl99 said:
@JimmyinSD said:
@mblack said:
@IDVikingfan said:
MBlack, you make it sound as though I should know the strategy and thinking of the white house medical staff.  Sorry, don't know, never been in the loop!  I'm also not a conspiracy theorist so don't know what the conspiracy folks believe relative to the POTUS and medical staff.  I don't believe the POTUS had a covid 19 infection but that's purely a guess on my part.

We have people on this forum say that HCQ has been proven ineffective, with no qualification.

You are asking non medical professionals on a football forum to assess the decision of the WH medical staff.  Good luck with that...  No one can answer your question.  A practicing physician could not accurately answer without more information.  Medical information of all POTUS is private and never released in total.  Yes, new releases when there is news to share but not full release of all information.
Thats fair. However this is what we do know and it is all public info...
  1. President says he does not have COVID and is tested regularly
  2. President says he is taking HCQ
  3. HCQ is a prescription med and President said he was prescribed it
  4. Research says HCQ does not prevent COVID-19
All these are in the public domain so I am sorry we don't need WH to tell us anything. We already know that from the President. So based on the above, do you think the President was right to takestrongly and frequently state that taking HCQ would prevent one from getting COVID-19? That question is not hard nor does one need a medical background to answer. Failure to answer as a matter of fact makes someone question why the question is being avoided.

I never heard him specifically advocate its use as a preventative measure,  despite him using it as such.  I do recall him touting it as a potential game changer in response to the success being seen with it in conjunction with zpac by doctors in France and other countries if administered early in a patients showing symptoms.

Much has been said about its failures but most studies dont say of it was used with zpack and the one study I did read the used it bn in conjunction with zpack said that it was only administered to the most severe patients after they were well past initial symptoms shown.

As far as should it be used as a preventative...if it doesnt affect other things then I say its worth a shot.  Half of medicine is about the patients confidence in the treatment so if he thinks it helps
...who cares?  Doctors are not going to act on what trump says and if they do they should have their medical licenses revoked.  

It's a long standing drug with well documented side effects and known issues as well as uses.  Aside from dumb asses that drink fish cleaner or drink lysol what did it really hurt for trump to try and sell some hope at a very dark time for a lot of people?

It was a single French researcher with a very flawed study, quickly refuted retracted by the publication that printed it, IIRC.  Got to love your consistency, you hang on this and the challenge any climate science with Scientists don't agree.

Glad I can keep you entertained.
Reply

[Image: p2ob4wte9ywk.jpg]
Reply

Reply

Reply

In other news Archer Daniel's Midland stocks plummet.


Reply

Here's something we can all agree on...Fingers/toes crossed:
==========================


Final tests of some COVID-19 vaccines to start next month
By LAURAN NEERGAARD Associated PressJune 11, 2020 — 1:20pm
The first experimental COVID-19 vaccine in the U.S. is on track to begin a huge study next month to prove if it really can fend off the coronavirus, while hard-hit Brazil is testing a different shot from China.

Where to do crucial, late-stage testing and how many volunteers are needed to roll up their sleeves are big worries for health officials as the virus spread starts tapering off in parts of the world.
Moderna Inc. said Thursday the vaccine it is developing with the National Institutes of Health will be tested in 30,000 people in the U.S. Some will get the real shot and some a dummy shot, as scientists carefully compare which group winds up with the most infections.
With far fewer COVID-19 cases in China, Sinovac Biotech turned to Brazil, the epicenter of Latin America's outbreak, for at least part of its final testing. The government of São Paulo announced Thursday that Sinovac will ship enough of its experimental vaccine to test in 9,000 Brazilians starting next month.
If it works, "with this vaccine we will be able to immunize millions of Brazilians," said São Paulo´s Gov. Joao Doria.
Worldwide, about a dozen COVID-19 potential vaccines are in early stages of testing. The NIH expects to help several additional shots move into those final, large-scale studies this summer, including one made by Oxford University that's also being tested in a few thousand volunteers in Brazil.
There's no guarantee any of the experimental shots will pan out.
But if all goes well, "there will be potential to get answers" on which vaccines work by the end of the year, Dr. John Mascola, who directs NIH's vaccine research center, told a meeting of the National Academy of Medicine on Wednesday.
Vaccines train the body to recognize a virus and fight back, and specialists say it's vital to test shots made in different ways — to increase the odds that at least one kind will work.
Sinovac's vaccine is made by growing the coronavirus in a lab and then killing it. So-called "whole inactivated" vaccines are tried-and-true, used for decades to make shots against polio, flu and other diseases — giving the body a sneak peek at the germ itself — but growing the virus is difficult and requires lab precautions.
The vaccine made by the NIH and Moderna contains no actual virus. Those shots contain the genetic code for the aptly named "spike" protein that coats the surface of the coronavirus. The body's cells use that code to make some harmless spike protein that the immune system reacts to, ready if it later encounters the real thing. The so-called mRNA vaccine is easier to make, but it's a new and unproven technology.
Neither company has yet published results of how their shots fared in smaller, earlier-stage studies, designed to check for serious side effects and how well people's immune systems respond to different doses.
Even before proof that any potential vaccine will work, companies and governments are beginning to stockpile millions of doses so they can be ready to start vaccinating as soon as answers arrive.
In the U.S., a program called "Operation Warp Speed" aims to have 300 million doses on hand by January. Under Brazil's agreement with Sinovac, the Instituto Butantan will learn to produce the Chinese shot.
Reply

8 things we got wrong at first about COVID-19Our understanding of the virus continues to change. Here's what we know now.
By Lisa M. Krieger East Bay TimesJune 13, 2020 — 4:24pm

A lot of our early assumptions about the new coronavirus have flip-flopped.
This is normal. That’s how science works — it’s a process of being less and less wrong over time. COVID-19 is new, so there’s lots of uncertainty. And the pandemic’s size and scale caught us by surprise. As we learn more, our understanding of the virus continues to change.
Here’s what we now know:
Masks are useful after all
Were you dubious about the U.S. Centers for Disease Control’s early assertion that mask “leakage” meant that it wouldn’t protect you from a virus? Join the crowd.
The CDC has since reversed its position. And an influential study in the Annals of Internal Medicine — which concluded that masks do not effectively stop virus-laden droplets — was retracted due to statistical problems.
Now we wear them everywhere — indeed, they’re often required. While masks don’t offer perfect protection, any kind of impediment is better than nothing. And if you’re sick, a mask can help keep you from spreading the virus to others.
Don’t just blame China; our early cases came from all over
To be sure, the crisis first emerged in the central Chinese city of Wuhan. So that’s where U.S. authorities focused their attention. In fact, the only way you could get a test was if you had recently traveled there, or had contact with someone known to be infected.
A new UC San Francisco genetic analysis reveals that California’s viral lineages are as diverse as we are. While some early infections can be traced to China, several others arrived here from Europe. Domestic travel was also to blame: Of the 20 first travel-related cases at UCSF, 14 were linked to travel within the U.S., including six from New York.
It’s less deadly than we first feared
Early on, death rates varied widely by geography — but they were all scary, ranging from 2% in South Korea, 4.3% in the U.S. and 13% in Italy. While we assumed the risk would drop as testing expanded and infected people recovered, we didn’t have reliable numbers.
With more data emerging, the CDC has revised the estimate downward. The current U.S. death rate for those showing symptoms ranges from 0.2% to 1%, with a “best estimate” of 0.4%. That’s still much higher than the seasonal flu’s 0.1% death rate — but it’s better than we feared. Still, until there is a vaccine, we are all vulnerable. And the death rates for some people, such as elders and those with other illnesses, remain extraordinarily high.
It’s spreading more slowly
Initial estimates suggested that each person with the virus could infect two to four people — a rate that would quickly accelerate an outbreak, if nothing is done to reduce it. A subsequent study from Los Alamos National Laboratory placed it even higher: 5.7.
Experts now calculate that the nation’s current transmission rate ranges from .90 to .95. That’s great news: A value under 1 signals fewer new cases in an area, whereas a value of over 1 means more cases.
What’s changed is our behavior, not the virus. Tough restrictions, such as stay-at-home orders, reduced infections. And if we let down our guard, it could pop back up again. Already, there are hints that reopening and relaxed behaviors are contributing to transmission rates over 1.1 in Utah and South Carolina.
It’s not just a respiratory disease
Many early symptoms seemed to involve the lungs. Patients had pneumonia, coughed and couldn’t breathe.
Now we know that the virus can attack other parts of the body. In April, the CDC added new symptoms, such as sore throat, muscle aches and fever. Gastrointestinal problems, such as diarrhea and nausea, have also been reported. Some people complain of loss of smell and taste and neurological symptoms, like dizziness. An infection can even cause mysterious and painful lesions on the toes, weeks after acute illness.
And, disturbingly, a growing body of evidence suggests that patients are suffering from strokes as a result of blood clots.
Your mail probably won’t kill you
Remember wiping down every letter, package and groceries? It made sense, at the time. We were anxious about lab studies showing the virus could live hours, even days, on surfaces.
Now, with months of experience under our belt, we know that it’s close contact with others — often during gatherings of friends, family or co-workers — that is driving the spread of the virus. Experts say the highest risk of infection is in enclosed, crowded and connected environments, such as households, meatpacking plants, prisons, churches and nursing homes.
Your bag of lettuce is not a main driver of the epidemic. Or that letter from Aunt Nancy.
Children aren’t completely safe
In those dark days of the pandemic, there was this silver lining: Not a single California child died. While kids make up 22.5% of the population, they’re only 5.7% of COVID-19 cases. And their illnesses are milder.
But the emergence of a rare complication shows that youth are not completely spared. The CDC reports that a serious inflammatory reaction — called “multisystem inflammatory syndrome in children” (MIS-C) — causes rashes, a persistent fever, abdominal pain and diarrhea. There have even been cases of heart failure.
You were smart to store toilet paper
The panic-stricken rush on toilet paper was one of the most bewildering moments of February and March. We were scolded for being hoarders, accused of fear and greed. After all, COVID-19 isn’t a diarrheal disease. How much toilet paper does any one family really need?
Here’s what we’ve come to appreciate: It kept us home. When infections were skyrocketing, we weren’t wandering the aisles of CVS or Costco.
And because we’re home, we need more of it. With an estimated three-quarters of the U.S. population under stay-at-home orders, we’re not visiting the commode at work, school, restaurants or coffee shops. Toilet paper manufacturer Georgia-Pacific calculates that home usage is up 40%. To last just two weeks, a four-person household would need 17 double rolls.
In a short six months, we’ve learned a lot about a once-mysterious pathogen and pandemic.
But much else remains maddeningly unclear — so many of today’s certainties will be tomorrow’s corrections.
Reply

and the narrative will all change, again and again and again.....
Reply

"It’s less deadly than we first feared"

This was incredibly irresponsible by the medical community and the media for severely overhyping how deadly this was. The projections that were being thrown around were apocalyptic and so overblown. 
Reply

Reply



Forum Jump:


Users browsing this thread:
3 Guest(s)

Powered By MyBB, © 2002-2025 Melroy van den Berg.